Background and aims: Infection with high-risk (HR) genotypes of the human papil-
While large-scale screening and vaccination programs have begun to address HPV morbidities in women, men are not spared from potentially cancerous HPV infection. Men can succumb to complications stemming from LR HPV infection (nominally, genital warts) and HR HPV infection (such as penile and anal cancers), although the course of naturally acquired HPV infections in men is less studied than that of women with cervical infections. 10 However, in contrast to women, men are far less likely to develop HPV-related cancers, despite harboring persistent infection with HR HPV and having lower HPV seroprevalence compared with women. 11, 12 The combination of these facets of HPV infection in men (HIM) have led to the reputation of men as a viral reservoir. 13 Additionally, a woman's risk of developing cervical cancer has been shown to be related to the sexual behavior patterns of males with HPV. 14 Thus, here, we hope to shed light on the role of males as a viral reservoir and the critical role that prophylactic and/or therapeutic vaccination in males can play in reducing HR HPV-related morbidity in both sexes.
| GENITAL, OROPHARYNGEAL, AND ANAL HPV INFECTION IN MEN
In comparison with women, men are much less likely to incur genital HPV complications. 15 Although women may presently carry a higher genital HPV disease burden, current epidemiologic trends show decreasing incidence of cervical dysplasia and cancer in developed nations, largely due to routine Pap screening but aided in part by prophylactic vaccination. 5, 16, 17 In contrast to routine Pap testing in conjunction with HPV DNA testing in women, no such screening tests are currently available for men. 18 In a research setting, numerous groups have reported HPV DNA testing at numerous genital sites, including the glans penis, coronal sulcus, urethra, scrotum, and perineum. [19] [20] [21] [22] [23] The HIM cohort study of 1159 men residing in Brazil, Mexico, and the United States estimated the prevalence of any HPV, oncogenic HPV, and nononcogenic genotypes at 50%, 30%, and 38%, respectively, using samples from the coronal sulcus, glans penis, penile shaft, and scrotum. The same study reported a median time to clearance of oncogenic HPV genotypes of 7.2 months and 12.2 months for HPV 16 specifically. 24 While penile HPV prevalence may vary based on sampling/screening techniques, these persistent penile HPV infections pose a risk of disease progression. Although cancers of the penis are rare, penile oncogenesis arises due to persistent infection with HR genotypes of HPV, and first present as penile intraepithelial neoplasia (PIN). 25, 26 HR genotypes of HPV, including HPV 16, are associated with the development of PIN in younger men. 27 Initial low-grade PIN lesions typically resolve within 2 years;
however, similar to CIN, a small minority of cases may progress to high-grade PIN lesions 28, 29 that could result in invasive cancer. In fact, a meta-analysis of 1266 invasive penile squamous cell carcinoma cases from 30 studies demonstrated an HPV prevalence of 47.9%, with an HPV 16 and/or HPV 18 prevalence of 36.7%. 25 Penile cancer in the United States has an incidence rate of approximately one per 100 000, while the incidence in developing nations can be much higher. 11 Uganda, for example, has an estimated agespecific incidence of penile cancer 30 of 4.4 per 100 000. An exact mechanism to explain this incidence difference has yet to be described, but several theories exist. Penile HPV infection and PIN are known to occur at higher rates in immunocompromised patients, such as patients infected with human immunodeficiency virus (HIV). 31, 32 While Ugandan adult HIV seroprevalence has dropped from approximately 14% in 1990, at the peak of the HIV epidemic, to approximately 5% in 2007, adult HIV infection and its sequelae remain a major public health concern. 33 An interesting trend discussed in great detail elsewhere 34, 35 is the reduced risk of penile HPV infection in circumcised males compared with uncircumcised males. While a biological mechanism has yet to be described, numerous studies have shown a lower incidence of overt penile cancer, PIN lesions, and penile HPV DNA detection in circumcised men compared with uncircumcised men. [36] [37] [38] [39] Examining both the effects of HIV serostatus and circumcision status, one group has shown a dually protective effect of circumcision and HIV-negative serostatus in sub-Saharan African men. 40, 41 Identifying factors influencing or exacerbating male genital HPV infection complications is an area of active research and continues to provide etiologic bases for understanding the natural history of male penile HPV infection.
A facet of HPV infection that has gained greater appreciation in recent years is the link between HPV infection and head/neck malignancies, most notably, oropharyngeal squamous cell carcinomas (OSCCs). Cancers of the head and neck can be divided into two distinct forms, which vary in epidemiology, etiology, and treatments. 42 Traditionally, oropharyngeal cancers have been linked primarily to tobacco use, but also to alcohol, poor oral hygiene, and certain genetic predispositions. 43 These non-HPV-related head and neck cancers have been declining in recent years concomitantly with declines in tobacco use. 44 However, incidence of HPV-associated oropharyngeal cancer appears to be rising. 45 It is now appreciated that some 40% ; however, current HPVrelated cancer incidence trends underscore the opposite. In the United
States, the incidence of HPV-related OSCC in men has exceeded the incidence of cervical cancer, which is on the decline. 56 In light of this increased prevalence of both HPV infection and overt OSCC in males, further attention must be given to male patients in both prophylaxis and screening.
The causal link between cervical HPV infection and associated cervical dysplasia and carcinoma has a similar parallel in anal HPV infection, anal dysplasia, and its progression to invasive carcinoma. In both men and women, showed anal HPV prevalence of 8%. 63 A 2008 study of MSW with no self-reported lifetime history of sex (oral or anal) with men showed a prevalence of anal HPV of 24.8%. These authors also reported a 34.4% concordance rate between the HPV types detected at anal (anal canal and perianal region) and genital (urethra, glans penis, penile shaft, and scrotum) sites. 64 A 2010 study from the HPV in men (HIM) cohort identified anal canal HPV prevalence at 12.0%, although this study's MSW population included men who may have had sex with one or two men in their lifetime, but not recently. 65 A final study from the HIM cohort directly compared MSW (n = 1305) and MSM (n = 176) and showed anal canal HPV prevalence of 12.2% and 47.2%, respectively. 66 In the MSM population of this study, a younger age and higher numbers of sexual partners were independently associated with detection of HPV in the anal canal. Although anal cytology screening has been performed, its predictive value of oncogenic progression (including a time frame) remains controversial. 11 The prevalence statistics of the aforementioned studies may vary due to differences in HPV DNA detection techniques or study population heterogeneity, and others report evidence of auto-innoculation from genital and manual sites. 74, 75 Nonetheless, there is a small but substantive body of evidence that male anal HPV infection can occur in the absence of a history of anal intercourse.
Because the overwhelming majority of HPV infections resolve within 2 years, an important epidemiological aspect of male HPV infection is seroprevalence, which can provide a measure of viral exposure. Serum antibodies may serve as a surrogate marker for ongoing or previous infections, or even lifetime exposure. [76] [77] [78] [79] [80] Anti-HPV coverage referenced concerns about vaccine affordability due to its cost. 131 Vaccine cost has also been reported to contribute to delayed or low vaccine uptake in low-and middle-income countries. 132 In MSM, concerns of vaccine cost have been shown to negatively affect intent to become vaccinated. 49 Other multilevel factors, such as the delayed adoption of sexneutral vaccination policies, demographic differences among vaccineeligible males, and geographic variation have contributed to low vaccination rates among men. The principal contributing factor to lower vaccination rates among eligible males, particularly in high-income countries with national HPV vaccination policies, is the delayed adoption of sex-neutral vaccination policies and publicly funded programs. 133 For instance, both Australia and the United States adopted male vaccination recommendations many years after the initial recommendation for the vaccination for females. Although not found consistently, socio-demographic variation exists for prophylactic HPV vaccination coverage among boys and men. 134 A national study among adolescents in the United States found that HPV vaccination coverage was lowest among non-Hispanic white boys compared with boys of all other races and ethnicities. 114 Examination of regional differences found that vaccination coverage was lowest among boys in the southern United States compared with boys in other regions of the United States and was lower among boys living in households at or above the poverty level compared with boys in households living below poverty. 114 Another study found that boys living in less densely populated nonurban areas had lower odds of initiating and completing the HPV vaccination series compared with boys from more urban areas. 135 Sexual behavior and self-reported HIV status are also important factors to consider in the examination of HPV vaccination rates among adult men. Data from the 2014 National HIV Behavioral Surveillance found that 17.2% of MSM ages 18 to 26 years and 37.2%
of HIV-positive MSM ages 18 to 26 had received at least one dose of HPV vaccine, which are higher than rates found among men in the general population. 136 Newman et al conducted a systematic review and meta-analysis that identified factors across 23 studies that examined HPV vaccine acceptability among males. 134 The factors that were most positively correlated were health care professional recommendation and perceived benefits of HPV vaccination. These results were similar to those of a systematic review that reported that the vaccine acceptability for girls was higher in the United States with a belief in vaccine effectiveness, a physician recommendation, and high likeliness of acquiring HPV. 137 However, weaker and less consistent provider recommendations would likely have contributed to a lower rate of HPV vaccination among males compared with females. 138 Research has found that despite current more sex-neutral HPV vaccination recommendations, health care providers provide less consistent and weaker HPV vaccination recommendations to males compared with females. 139 In European countries at a time when HPV vaccination was only available for girls, parental acceptance of HPV vaccination for boys was as high as that for girls. This was particularly true in countries with active vaccination policies such as the United Kingdom and
Italy. 140 Taken together, dissemination of perceived benefits and strong recommendations by health care providers are two factors grounded in health behavior theory that are closely associated with vaccine uptake by eligible males. conversations between men and their health care providers, which in turn may allow men to feel comfortable discussing male-male sexual activity.
| THERAPEUTIC VACCINATION
Finally, policy changes that reduce financial barriers to HPV vaccination among eligible patients must be addressed in both first-time and "catch-up" vaccine recipients. Given the nature of this critical public health issue in both men and their sexual partners, a combination of these strategies is recommended by the Community Preventative Services Task
Force and the Advisory Committee on Immunization Practices.
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